A Multicenter, Open-Label Study With a Randomized Control Arm of the Efficacy, Safety, and Pharmacokinetics of Intravenously Infused Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme After Failure of Standard First Line Therapy
Latest Information Update: 12 May 2025
At a glance
- Drugs Berubicin (Primary) ; Lomustine
- Indications Glioblastoma
- Focus Registrational; Therapeutic Use
- Sponsors CNS Pharmaceuticals
Most Recent Events
- 04 May 2025 Planned End Date changed from 31 Mar 2025 to 31 Mar 2026.
- 04 May 2025 Planned End Date changed from 1 Mar 2025 to 31 Mar 2025.
- 04 May 2025 Planned primary completion date changed from 1 Dec 2024 to 1 Feb 2026.